Science to practice: The dawn of molecular US imaging for clinical cancer imaging

Radiology

Volumn 256, Issue 2, 2010, Pages 331-333

  Kiessling, Fabian ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; MICROBUBBLE; MOLECULAR IMAGING; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; ULTRASOUND; WHOLE BODY IMAGING; DRUG DELIVERY SYSTEM; ECHOGRAPHY; GENETIC PROCEDURES; HUMAN; IMAGE ENHANCEMENT; PROCEDURES; TRENDS;

CONTRAST MEDIUM;

CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; HUMANS; IMAGE ENHANCEMENT; MOLECULAR PROBE TECHNIQUES; NEOPLASMS; ULTRASONOGRAPHY;

EID: 77955147104     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.100717     Document Type: Short Survey

References (7)

1. Kiessling F, Huppert J, Palmowski M. Functional and molecular ultrasound imaging: concepts and contrast agents. Curr Med Chem 2009;16(5):627-642.
2. Pysz MA, Foygel K, Rosenberg J, Gambhir SS, Schneider M, Willmann JK. Anti-angiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010; 256 (2): 519-527.
3. Willmann JK, Paulmurugan R, Chen K, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008; 246 (2): 508-518.
4. Palmowski M, Huppert J, Ladewig G, et al. Molecular profi ling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol Cancer Ther 2008; 7 (1): 101-109.
5. Korpanty G, Carbon JG, Grayburn PA, Fleming. JB, Brekken RA. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007; 13 (1): 323-330. (Pubitemid 46121886)
6. Hauff P, Reinhardt M, Briel A, Debus N, Schirner M. Molecular targeting of lymph nodes with L-selectin ligand-specific US contrast agent: a feasibility study in mice and dogs. Radiology 2004; 231 (3): 667-673. (Pubitemid 38668081)
7. Pochon S, Tardy I, Bussat P, et al. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol 2010; 45 (2): 89-95.